Literature DB >> 12406644

CYP2C9 allelic variants: ethnic distribution and functional significance.

Hong-Guang Xie1, Harish C Prasad, Richard B Kim, C Michael Stein.   

Abstract

Cytochrome P-450 (CYP) 2C9 CYP2C9 is a polymorphically expressed enzyme responsible for the metabolism of several clinically important drugs, some with a low therapeutic index. This review summarizes the structure-function relationship of the CYP2C9 promoter and coding regions, known polymorphisms, the functional significance of various CYP2C9 alleles in vitro and in vivo, and their population frequencies. In addition, possible molecular mechanisms underlying ethnic variability in the metabolism of CYP2C9 substrate drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406644     DOI: 10.1016/s0169-409x(02)00076-5

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  70 in total

1.  Technologies in the Whole-Genome Age: MALDI-TOF-Based Genotyping.

Authors:  Nicolas Vogel; Katrin Schiebel; Andreas Humeny
Journal:  Transfus Med Hemother       Date:  2009-07-10       Impact factor: 3.747

2.  Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.

Authors:  Yuanyuan Dong; Huasheng Xiao; Qi Wang; Chunxiu Zhang; Xiuming Liu; Na Yao; Haihui Sheng; Haiyan Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese.

Authors:  Chen-Hui Luo; An Wang; Rong-Hua Zhu; Wei-Xia Zhang; Wei Mo; Bang-Ning Yu; Guo-Lin Chen; Dong-Sheng Ou-Yang; Xiao-Hong Duan; A M Abd El-Aty; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 4.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 5.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 6.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.

Authors:  Wei Zhang; Yi-Jing He; Chun-Ting Han; Zhao-Qian Liu; Qing Li; Lan Fan; Zhi-Rong Tan; Wei-Xia Zhang; Bang-Ning Yu; Dan Wang; Dong-Li Hu; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

Review 8.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

9.  Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship.

Authors:  Hong-Jaan Wang; Li-Heng Pao; Cheng-Huei Hsiong; Tung-Yuan Shih; Meei-Shyuan Lee; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

Review 10.  Understanding the pharmacogenetic approach to warfarin dosing.

Authors:  Ingrid Glurich; James K Burmester; Michael D Caldwell
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.